Eli Lilly and Company’s Stock Price Soars to $803.17, Marking a Stellar 2.55% Increase

Eli Lilly and Company (LLY)

803.17 USD +19.99 (+2.55%) Volume: 4.33M

“Eli Lilly and Company’s stock price surges to 803.17 USD, marking a positive change of +2.55% this trading session, with a significant trading volume of 4.33M. The pharmaceutical giant showcases a robust performance, with a year-to-date percentage increase of +37.78%, making it a compelling choice for investors.”

Latest developments on Eli Lilly and Company

Eli Lilly’s stock price has been on the rise recently, with key events leading up to this surge. The company’s diabetes drug tirzepatide received approval in China, while their weight-loss drug was cleared for diabetes treatment in the country as well. A study showed that more than half of Crohn’s disease patients treated with Lilly’s mirikizumab achieved clinical remission. Additionally, Eli Lilly partnered with a Boston biotech company to develop cancer treatments, and their stock hit new highs after a regulatory win in China. The company also secured a deal worth over $1.1 billion to develop new radiopharmaceuticals. With promising phase 3 results for their once-weekly insulin efsitora in type 2 diabetes, Eli Lilly’s stock is on pace for a record close, showing strong performance in the market.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company seems to have a positive long-term outlook. With a high momentum score of 4, the company is showing strong performance and growth potential. Additionally, a growth score of 3 indicates promising prospects for future expansion and development. While the value, dividend, and resilience scores are not as high, the overall outlook for Eli Lilly & appears to be optimistic.

Eli Lilly & Company is a pharmaceutical company that focuses on discovering, developing, manufacturing, and selling products for both humans and animals. With a diverse product portfolio that includes neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products, the company serves markets worldwide. The Smartkarma Smart Scores reflect a company with solid momentum and growth potential, suggesting a positive trajectory for Eli Lilly & in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma